Wechselwirkungen · Orladeyo
Orladeyo 72 mg film-coated granules in sachet Orladeyo 96 mg film-coated granules in sachet Orladeyo 108 mg film-coated granules in sachet Orladeyo 132 mg film-coated granules in sachet · Abschnitt 4.5 · PDF-Seite 18
HOS-144619 · Präparat HOS-099216
CYP3A4 substrates Berotralstat is a moderate inhibitor of CYP3A4, increasing the Cmax and AUC of oral midazolam by 45% and 124%, respectively, and the Cmax and AUC of amlodipine by 45% and 77%, respectively. Concomitant administration may increase concentrations of other medicinal products that are CYP3A4 substrates. Refer to the SmPC for concomitant medicinal products that are predominantly metabolised by CYP3A4, particularly those with a narrow therapeutic index (e.g. ciclosporine, fentanyl). Dose adjustments of these medicinal products may be required (see section 5.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amlodipine (HOS-086287) fentanyl (HOS-086196) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-06T11:50:00Z · SHA-256 677e4228648fad20ff699c4fdde1afae259098b3f1b5cce5f019599df82214db · Passage 5de44780d12273880b808053c0955ab3e830c9eab87d4b63ee59c04c1442abe7 · Zeichen 822–1401 im Abschnitt